Primary Endpoint Solutions
Optimizing Clinical Trials
Celia earned her Bachelor of Science in Public Health from the University of Massachusetts Amherst. In 2022, she began her career at Biomodels LLC as an Administrative Assistant supporting preclinical operations and has advanced to Associate Project Manager. Celia now works closely with the PES team, where she contributes to clinical initiatives and applies her experience in project management to support clinical operations. She is committed to improving health outcomes and brings valuable experience from both preclinical and clinical settings.
Dr. Diehl is a distance education and multimedia expert who has provided direction to PES since the company’s founding. In his PES role, Will optimizes the design, content and enablement of our training activities. In addition to his work with PES, Will is a highly sought after consultant in the corporate, higher education, healthcare, and government sectors. He is also an associate professor and coordinator of online graduate programs in the Lifelong Learning and Adult Education program in the College of Education at Penn State University.
He serves as Associate Editor for The American Journal of Distance Education, is the Director of The American Center for the Study of Distance Education, and co-editor of the Handbook of Distance Education (4th edition). Will’s distance learning expertise is supplemented by his significant and diverse experiences in education and technology.
Charlotte Dowden joined Primary Endpoint Solutions in 2018 as a Clinical Research Associate and currently serves as a Senior Project Manager. Prior to PES, she conducted research on neurodegenerative diseases in the Nock Lab at Harvard University and managed pediatric autism research at Massachusetts General Hospital in collaboration with Autism Speaks, Autism Care Network.
Charlotte also previously led Operations for Harvard Alumni for Mental Health, a nonprofit organization, where she now serves on the Board. She earned her Bachelor of Science from the University of Massachusetts Amherst and her MPH from Columbia University.
Dr. Alessandro Villa is a clinical indication expert in oral and maxillofacial diseases, who joined PES in 2016. He is currently the Chief of Oral Medicine and Oral Oncology at Miami Cancer Institute. Previously, he served as Chief of Oral Medicine and Director of Oral Oncology at the University of California San Francisco (UCSF), where he was also Program Director for the Oral Medicine Residency Program.
Earlier in his career, Dr. Villa was an Associate Surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, and served as Program Director for the Oral Medicine Residency Program at Harvard University. His research focuses on oral complications of cancer therapy, including mucositis. He has published extensively on cancer regimen toxicities, epidemiology of oral and oropharyngeal cancers, and disparities in treatment outcomes, and is a recognized clinical trialist.
As a co-founder of Primary Endpoint Solutions, Ms. Trewin serves as its Chief Financial Officer. Ms. Trewin also provides leadership at Biomodels as its Chief Financial Officer, bringing her extensive experience with pre-clinical research and medical diagnostic instrumentation companies, including Inter-Medico, NoAb BioDiscoveries, and LabOne. In addition, she has held public accounting and other industry positions at KPMG, Ernst Young and Avery Dennison.
Ms. Trewin holds a Bachelor of Commerce degree from the University of Toronto and is a member of Canadian Institute of Chartered Accounts and holds a CPA, CA designation.
Mr. Lichtman has been the Managing Partner at Biomodels since 2012. Following sales and marketing positions at Abbott, J+J and Bayer, He recognized opportunities presented by advances in medical technology and founded an in-vitro diagnostic instrumentation company when diagnostics was in its infancy and its distribution was an unsophisticated part of hospital supply. Additionally, Mr. Lichtman saw drug discovery as synergistic with diagnostics and founded a contract research organization. The success of both companies reflects Mr. Lichtman’s commitment to innovation and excellence. He brings his management skills as a CEO and his commitment to translational research to Biomodels to amplify the corporate philosophy of an employee-centric culture.
Dr. Sonis is a senior academic and research scientist who holds appointments at the Harvard School of Dental Medicine (HSDM), the Dana-Farber Cancer Institute (DFCI), and Brigham and Women’s Hospital (BWH). After receiving his DMD from Tufts, Dr. Sonis completed a combined doctorate and specialty training program at Harvard and was a Knox Fellow at Oxford (UK) where he studied tumor immunology.
In addition to his academic appointments, Dr. Sonis is the Chief Scientific Officer of Biomodels, LLC; Co-Founder and Chief Scientific Advisor of Inform Genomics; Past president of TRIAD Burden of Illness Studies, a not-for-profit company focusing on the adverse health and economic outcomes of cancer toxicities.
As a co-founder of PES, Dr. Lyng is responsible for the oversight of all PES research collaborations. Dr. Lyng’s scientific expertise lies in translational research spanning the areas of inflammatory disease, cancer supportive care, oncology, and diseases of the central nervous system. Dr. Lyng received his Ph.D. in Biomedical Sciences from the University at Albany School of Public Health and his B.S. in Neuroscience from St. Lawrence University. In addition to his role at PES, Dr. Lyng is the Chief Operating Officer at Biomodels, LLC where he is responsible for the oversight of their preclinical/translation research programs.